Autonomics and Hypertension

Questions discussed in this category

How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?

ESPRIT Trial

1 Answer available

How do you approach long-term blood pressure parameters in ischemic stroke patients with severe symptomatic intracranial stenosis?

How do you balance between having a higher long-term blood pressure to prevent flow failure and leading to worsening of stenosis or occlusion from the...

2 Answers available

What treatments options may be considered in patients with POTS who also need daily diuretics to treat heart failure and are already wearing compression garments?

3 Answers available

What are your top takeaways from ACC 2024?

3 Answers available

Do you recommend bedtime administration of antihypertensives in patients who exhibit nondipping on ambulatory blood pressure monitoring?

3 Answers available

Which class(es) of antihypertensives do you recommend for first-line therapy for hypertension in severe aortic stenosis?

1 Answer available

What are your top takeaways from AHA 2023?

4 Answers available

Can Droxidopa be used for augmenting orthostatic hypotension treatment in patients who are already on midodrine and/or fludrocortisone?

Is there an approach to tapering the other two medications while uptitrating Droxidopa dosing to reduce the risk of supine hypertension?

1 Answer available

When should we consider using acarbose for postprandial hypotension?

1 Answer available

Should vasodilatory therapies be considered first-line in the management of hypertension in patients with severe aortic regurgitation?

2 Answers available

What is your approach to initiating and titrating midodrine for both inpatient and ambulatory settings?

1 Answer available

Papers discussed in this category

Journal of cardiovascular imaging, 2018 Jun 22

Antihypertensive Treatment in Severe Aortic Stenosis.

Circulation, 2023 Nov 13

Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study.

Circulation, 2023 Nov 11

Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS).

Circulation. Cardiovascular quality and outcomes, 2023 Nov 06

Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients with Atrial Fibrillation in the United States.

American heart journal, 2017 Apr 24

Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.

The New England journal of medicine, 2023 Nov 11

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

American heart journal, 2023 Mar 25

Screening for peripartum cardiomyopathies using artificial intelligence in Nigeria (SPEC-AI Nigeria): Clinical trial rationale and design.

JAMA, 2023 Nov 11

Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial.

American heart journal, 2020 Oct 13

Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

The New England journal of medicine, 2024 Apr 07

Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.

Circulation, 2016-12-13

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

American heart journal, 2022 May 17

Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.

The New England journal of medicine, 2024 Apr 06

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Lancet (London, England), 2024 Jun 27

Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.

Autonomics and Hypertension

Questions discussed in this category

Papers discussed in this category

Related Topics